Thesis: Natera is a real, fast-growing, cash-generative genomic-testing franchise and a top-7 IBB weight — but its own leading composite is bearish at RSI 77, so we watch the franchise rather than chase the extended price.

Verdict: WATCH, conviction LOW. The TAPE passes trend-hold confirmation — strong-up, golden cross active, near the 52wk high — but the quality signals contradict it. A 25% earnings beat rate (it misses three of four) plus insider selling drive the leading composite to BEARISH (−0.8), and the name is extended (RSI 77, +19% above SMA20). A high-RSI name whose own quality composite is bearish is not a chase. Strong price, weak quality. Revisit when the beat-rate / insider tape turns AND a pullback resets the setup.

The Story Right Now

Natera ($NTRA) is a genomic-testing leader: Signatera (molecular residual disease / oncology recurrence monitoring) and Panorama (prenatal). The top line is big, fast, and self-funding — $2.31B FY2025 revenue, +38.8% +35.9% YoY (correction 2026-08-03: the filed year grew +35.9% over FY2024's $1.70B; +38.8% is Q1 2026's year-over-year rate, mislabeled onto the annual figure), and +$215M operating cash flow despite GAAP losses. Quarterly revenue keeps stepping up: $546.6M (Q2'25) → $592.2M (Q3'25) → $696.6M (Q1'26).

It surfaced through the June 29 IBB breadth-decomposition investigation: NTRA is a top-7 IBB weight at 2.7% and one of the index leaders by price (+46%/3m). It was a coverage gap until now and has been added to the new ibb watchlist.

The tension is the whole story. The tape is hot — $272.31, RSI 77, strong-up, golden cross active, −0.93% off the 52wk high, +45.75% over 3m. But the leading composite reads BEARISH (−0.8): revenue growth flagged bearish (the +38.8% YoY is decelerating on a rate basis), a 25% earnings beat rate, and bearish insider trading. Real franchise, extended price, weak quality signals.

Setup

• Entry zone: WATCH only. RSI 77 and +19% above SMA20 with a bearish leading composite. No entry until the beat-rate / quality signals improve or a pullback toward SMA20 (~$229) resets the tape.
• Stop: if held, below the SMA50 (~$214); a clean break voids the uptrend structure.
• Target: n/a while on watch. A quality turn (beat-rate, insider) plus a reset entry would be needed first.
• Conviction: LOW. The trend-hold lens passes on price (strong-up, golden cross, near highs) but the quality lens fails (25% beat rate, insider selling → composite −0.8) and the name is extended.

Bull case

• Large, fast-growing top line: $2.31B FY2025 revenue, +35.9% YoY (Q1'26 ran +38.8%), with sequential quarterly steps to $696.6M in Q1'26.
• Operating-cash-flow positive (+$215.3M FY2025) — the business funds itself despite GAAP net loss, which de-risks the franchise versus pre-revenue biotech.
• Two real product lines with durable demand: Signatera (MRD / oncology recurrence monitoring) and Panorama (prenatal).
• Index leadership: top-7 IBB weight (2.7%) and one of the strongest IBB names by price (+46%/3m); trend structure is intact (strong-up, golden cross, above all major SMAs).

Bear case

• Leading composite BEARISH (−0.8): the model's own read on the name is negative despite the price.
• 25% earnings beat rate — it misses three of four; the next quarterly result is a coin-flip-against, not a setup we want to chase at the high.
• Insider trading flagged bearish (selling into strength).
• Revenue growth flagged bearish on a rate basis — the +38.8% quarterly YoY is decelerating.
• Extended tape: RSI 77, +19% above SMA20, −0.93% off the 52wk high. Reward/risk into a high-RSI name with negative quality signals is poor.
• Still GAAP-unprofitable (operating income −$309.9M, net income −$208.2M, EPS diluted −$1.52 FY2025).

Catalysts

• The next quarterly report is the key watch item — given the 25% beat rate, the next readout carries outsized two-way risk. We are watching whether the beat-rate trend improves, not positioning ahead of it.
• Insider-activity turn: a shift from selling to neutral/buying would be a quality signal worth re-rating on.
• Tape reset: a pullback toward SMA20 (~$229) that unwinds RSI 77 would convert this from "chase" to a potential entry, conditional on the quality signals.
• Revenue-growth re-acceleration (or stabilization) on a rate basis would lift the bearish growth flag.

Financials

Figures from Natera's FY2025 SEC filings.

Leading-indicator read (leading NTRA): composite BEARISH (−0.8). Revenue growth is flagged bearish — the headline +38.8% YoY is decelerating on a rate basis. Earnings are bearish on a 25% beat rate (frequent misses), and insider trading is bearish. The pattern is a genuinely growing, cash-generative top line paired with quality signals that point the other way — which is why the franchise rates a watch, not a buy, at this price.

Balance-sheet note: treat reported cash as partial. The cash figure in EDGAR is dated ($466M as of 2022) and short-term investments are $1.0M (2025-09-30); the +$215.3M FY2025 operating cash flow is the cleaner liquidity read here than the stale cash line.

Cross-references

• The June 29 IBB breadth-decomposition investigation — source investigation; NTRA as top-7 IBB weight (2.7%) and a price leader (+46%/3m), flagged as a former coverage gap now added to ibb.
• Trend-hold lens: confirmed-uptrend, buy-the-pullback discipline this setup is filtered against.

Sources

• Price truth (settled Fri 2026-06-26 close): summaries — $272.31, RSI 77, strong-up, golden cross active; SMA20 $228.92, SMA50 $213.93, SMA200 $209.09; 30d +24.45%, 3m +45.75%, 1y +68.34%, −0.93% off 52wk high; VWAP $198.79, relative volume 1.06.
• Financials: the desk's own tooling (SEC EDGAR XBRL) — FY2025 revenue/income/EPS/operating cash flow and quarterly revenue series above.
• Leading-indicator composite: leading NTRA — composite BEARISH (−0.8); revenue growth, earnings (25% beat rate), and insider trading all flagged bearish.
• IBB context: 2026-06-29-ibb-at-all-time-highs-breadth-decomposition-of-the-ishares-nasdaq-biotechnology-.